

Variable phenotype in females with the same mutation could be explained by variations in expression due to differences in X inactivation among families, as suggested by Aradhya (2000). If so, an X-inactivation study could be helpful in predicting phenotypic outcome in a female heterozygote with the mutation. However, the proband in the family described here (HED-ID phenotype) and the female heterozygote in family XL344 (IP-like phenotype; Aradhya et al. 2001) yielded the same random X-inactivation pattern. We therefore suspect that an X-inactivation study would have limited predictive value.

To summarize, hypomorphic mutations in the *NEMO* gene can lead to the devastating HED-ID phenotype in female heterozygotes as well as males. The very broad phenotypic spectrum of female heterozygotes, ranging from normal to overt immunodeficiency, poses a challenge during counseling of families with HED-ID.

### Acknowledgments

This work was supported, in part, by a grant from Pharmacia Fund for Growth & Development Research and the Ministry of Education, Culture, Sports, Science & Technology of Japan. We would like to thank Drs. Akira Sakaguchi and Masashi Akiyama for referring the families.

KENJIRO KOSAKI,<sup>1,2</sup> NORIKO SHIMASAKI,<sup>3</sup>

HIROYUKI FUKUSHIMA,<sup>2</sup> MITSUHIRO HARA,<sup>3</sup>

TSUTOMU OGATA,<sup>1</sup> AND NOBUTAKE MATSUO<sup>1</sup>

<sup>1</sup>Department of Pediatrics and <sup>2</sup>Pharmacia Fund for Growth & Development Research, Keio University School of Medicine, Tokyo; and <sup>3</sup>Shimizu City Hospital, Shimizu, Japan

### Electronic-Database Information

Accession numbers and the URL for data in this article are as follows:

Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for IP [MIM 308300] and HED-ID [MIM 300291])

### References

- Akiyama M, Aranami A, Sakaki Y, Ebihara T, Sugiura M (1994) Familial linear and whorled nevoid hypermelanosis. *J Am Acad Dermatol* 30:831–833
- Aradhya S, Courtois G, Rajkovic A, Lewis RA, Levy M, Israel A, Nelson F (2001) Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of *NEMO* (*IKK-γ*). *Am J Hum Genet* 68: 765–771
- Landy SJ, Donnai D (1993) Incontinentia pigmenti (Bloch-Sulzberger syndrome). *J Med Genet* 30:53–59
- Parrish JE, Scheuerle AE, Lewis RA, Levy ML, Nelson DL (1996) Selection against mutant alleles in blood leukocytes

is a consistent feature in incontinentia pigmenti type 2. *Hum Mol Genet* 5:1777–1783

Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, Munnich A, Israel A, et al (2000) Genomic rearrangement in *NEMO* impairs NF-κB activation and is a cause of incontinentia pigmenti: the International Incontinentia Pigmenti (IP) Consortium. *Nature* 405:466–472

Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M, Shapira SK, Farndon PA, Wara DW, Emmal SA, Ferguson BM (2000) A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in *IKK-gamma* (*NEMO*). *Am J Hum Genet* 67:1555–1562

Address for correspondence and reprints: Dr. Kenjiro Kosaki, Division of Medical Genetics, Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. E-mail: kkosaki@sc.itc.keio.ac.jp

© 2001 by The American Society of Human Genetics. All rights reserved. 0002-9297/2001/6903-0021\$02.00

*Am. J. Hum. Genet.* 69:665–666, 2001

### Reply to Kosaki et al.

To the Editor:

The letter from Kosaki et al. (2001 [in this issue]) reports the first instance of immunodeficiency in a female heterozygous for a hypomorphic mutation of the X-linked *NEMO* gene. *NEMO* hypomorphic mutations result, in males, in the disorder hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID) (Zonana et al. 2000; Aradhya et al. 2001; Doffinger et al. 2001; Jain et al. 2001). In the 17 families previously reported, only males have had clinical immunodeficiency. As expected, owing to Lyonization, carrier females either were normal or had defects of their teeth, skin, or hair. A single female carrier, heterozygous for the same mutation reported in the family studied by Kosaki et al., had an elevated immunoglobulin A level (Zonana et al. 2000) but did not have immunodeficiency.

Null mutation of the *NEMO* gene generally results in prenatal lethality in hemizygous males and in incontinentia pigmenti in heterozygous females. Affected females are immunologically normal, presumably owing to preferential survival and proliferation of cells expressing the normal allele (skewed X inactivation). Female carriers with hypomorphic mutations have shown both random and skewed X inactivation, indicating that at least some of the mutations do not affect T- and B-cell survival or proliferation (Aradhya et al. 2001; Doffinger et al. 2001; Jain et al. 2001). Rarely, females can fully manifest X-linked recessive disorders, including other X-linked immunodeficiencies, such as Wiskott-Al-

drich syndrome (Puck and Willard 1998). However, in contrast to the patient reported by Kosaki et al., cases not due to cytogenetic abnormalities demonstrate skewed X inactivation, presumably of cells expressing the mutant allele. In these instances, the mutations do not impair cell proliferation or survival but still do cause cellular dysfunction.

It is difficult to reconcile Kosaki et al.'s finding of random X inactivation in the peripheral blood leukocytes with their patient's clinical manifestations. We would expect to find skewed X inactivation in which the X chromosome expressing the mutant allele is predominant. It is possible that a functionally important subset of B or T cells (Jain et al. 2001) would have displayed skewed X inactivation if Kosaki et al. had sorted the leukocytes into separate populations before analysis. Another remote possibility is that, unlike the patient's presumably heterozygous mother and sister, who had ectodermal findings but no immunodeficiency, the patient had a loss of her normal *NEMO* allele. The existence of a highly homologous *NEMO* pseudogene on the X chromosome makes it very difficult to distinguish hemizyosity from true heterozygosity.

Kosaki et al.'s findings are unique, but, as in other examples, fully manifesting females with X-linked recessive disorders—such as Duchenne muscular dystrophy and hemophilia B—usually represent rare events (Puck and Willard 1998). Families should still be counseled that generally, in HED-ID, only males manifest clinically significant immunodeficiency. Further cases of immunodeficient females with HED-ID must be described before such counseling should be altered.

JONATHAN ZONANA AND BETSY FERGUSON  
*Department of Molecular and Medical Genetics*  
*Oregon Health Sciences University*  
*Portland*

## References

- Aradhya S, Courtois G, Rajkovic A, Lewis R, Levy M, Israel A, Nelson D (2001) Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of *NEMO (IKK- $\gamma$ )*. *Am J Hum Genet* 68:765–771
- Doffinger R, Smahi A, Bessia C, Geissmann F, Feinberg J, Durandy A, Bodemer C, et al (2001) X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF- $\kappa$ B signaling. *Nat Genet* 27:277–285
- Jain A, Ma CA, Liu S, Brown M, Cohen J, Strober W (2001) Specific missense mutations in *NEMO* result in hyper-IgM syndrome with hypohidrotic ectodermal dysplasia. *Nat Immunol* 2:223–228
- Kosaki K, Shimasaki N, Fukushima H, Hara M, Ogata T, Matsuo N (2001) Female patient showing hypohidrotic ectodermal dysplasia and immunodeficiency (HED-ID). *Am J Hum Genet* 69:664–665 (in this issue)
- Puck JM, Willard HF (1998) X inactivation in females with X-linked disease. *N Engl J Med* 338:325–328
- Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M, Shapira SK, Farndon PA, Wara DW, Emmal SA, Ferguson BM (2000) A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in *IKK-gamma (NEMO)*. *Am J Hum Genet* 67:1555–1562

Address for correspondence and reprints: Dr. Jonathan Zonana, Department of Molecular and Medical Genetics, L-103, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97221. E-mail: zonana@ohsu.edu

© 2001 by The American Society of Human Genetics. All rights reserved.  
 0002-9297/2001/6903-0022\$02.00